ad image

Company Info

BIOVECTRA

BIOVECTRA

CDMO

Overview

BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.
BIOVECTRA
Contributions
23 Contributions1 / 2
Enabling Client Success with Complementary Services Built upon a Strong Chemistry Foundation
Process Chemistry

Enabling Client Success with Complementary Services Built upon a Strong Chemistry Foundation

Jean-Francois Vincent-Rocan, Ph.D.

BIOVECTRA

PAO-12-23-CL-02Dec 13, 2023
Building on Experience and Investing in an Integrated mRNA Offering
New Integrated mRNA Offering

Building on Experience and Investing in an Integrated mRNA Offering

Jessica Madigan; Normand Blais

BIOVECTRA

PAO-07-23-CL-03Jul 31, 2023
Managing Risk in Cutting-Edge mRNA Therapeutics
Risk Management in mRNA Manufacture

Managing Risk in Cutting-Edge mRNA Therapeutics

Jessica Madigan; Normand Blais

BIOVECTRA

PAO-07-23-CL-04Jul 31, 2023
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
mRNA

Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects

Scott Doncaster; Marc Sauer, Ph.D.

BIOVECTRA

PAO-02-022-CL-07Mar 12, 2022
Looking to Another 50 Years of Growth
CDMO

Looking to Another 50 Years of Growth

Heather Delage; Oliver Technow

BIOVECTRA

PAO-02-22-R250-01Feb 14, 2022
BIOVECTRA
mRNA Vaccines

BIOVECTRA mRNA Vaccine and Biomanufacturing Facility Announced

BIOVECTRA

PR-M11-21-02Nov 18, 2021
Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology
Single-Use Technology

Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology

Scott Doncaster; Cameron Graham; Neil Morrison

BIOVECTRA

PAO-10-21-CL-08-778Oct 20, 2021
BIOVECTRA
Rebranding

BIOVECTRA Inc. Looks Inward for New Brand: It’s All About Care

BIOVECTRA

PR-M06-21-013Jun 04, 2021
BioVectra's Strategic Brand Update
Branding

BioVectra's Strategic Brand Update

Oliver Technow

BIOVECTRA

PTV-06-21-CL-001Jun 02, 2021
Planning for Growth as Blockbusters Give Way to Personalized Medicine
Strategic Growth

Planning for Growth as Blockbusters Give Way to Personalized Medicine

BIOVECTRA

PAO-04-22-R221-54Apr 29, 2021
BioVectra and PhaseBio Discuss Creating an Optimal Partnership
Partnership

BioVectra and PhaseBio Discuss Creating an Optimal Partnership

Oliver Technow; David Alvaro, Ph.D.; Jonathan Mow

BIOVECTRA

PTV-04-21-CL-001Apr 15, 2021
BIOVECTRA
Supply Agreement

PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

BIOVECTRA

PR-M11-20-048Mar 11, 2021
Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation
Process Engineering

Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation

Scott Doncaster; Clarke MacDonald

BIOVECTRA

PAP-Q1-20-CL-017Mar 19, 2020
Living in Canada’s Coastal Paradise
Recruitment

Living in Canada’s Coastal Paradise

BIOVECTRA

PAP-Q3-19-CL-004Oct 28, 2019
BIOVECTRA
Transaction

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

BIOVECTRA

PR-M09-19-NI-037Sep 13, 2019
Announcing Expansion for Enhanced Capabilities
Expansion

Announcing Expansion for Enhanced Capabilities

Heather Delage

BIOVECTRA

PTV-M08-19-BIO-004Aug 19, 2019
Come Home to BioVectra
Company Overview

Come Home to BioVectra

BIOVECTRA

PAP-Q2-2019-CL-008May 24, 2019
Supporting Client Projects for CDMO Success
Small Molecule API

Supporting Client Projects for CDMO Success

Marc Sauer, Ph.D.; Mark Wellman

BIOVECTRA

PAP-Q1-2019-CL-030Mar 12, 2019
BIOVECTRA
API Manufacturing

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

BIOVECTRA

PR-M12-17-NI-013Dec 15, 2017
BioVectra on the Road to BIO: Bridging Microbial Demand with Expanded Capacity
Capacity Expansion

BioVectra on the Road to BIO: Bridging Microbial Demand with Expanded Capacity

Oliver Technow

BIOVECTRA

PTV-M06-17-CL-004Jun 21, 2017
1 / 2